Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy involving the use of psychotherapy and methylene blue, sometimes paired with red light (photobiomodulation) therapy, is being explored for its potential to enhance neuroplasticity, improve memory, and support mental health conditions such as depression, anxiety, and trauma-related disorders. Methylene blue is a synthetic compound with established medical uses that acts as a mitochondrial enhancer by facilitating electron transport in the respiratory chain. It has antioxidant, anti-inflammatory, neuroprotective, and antimicrobial properties. When combined with psychotherapeutic interventions—especially those targeting memory reconsolidation or fear extinction—methylene blue may augment therapeutic outcomes by improving cellular energy production in neural circuits involved in learning and emotional regulation[3][1][7]. This approach remains investigational but has shown promise in early studies for enhancing cognitive function and supporting recovery from mood disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psychotherapy + methylene blue.